查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1987534

蛋白質療法市場報告：按產品、治療領域、功能、地區和預測（2026-2034 年）

Protein Therapeutics Market Report by Product, Therapy Area, Function, Region and Forecast 2026-2034
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2025年全球蛋白質療法市場規模為3,889億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以5.48%的複合年成長率成長，到2034年達到6,379億美元。目前，北美是該市場的主要驅動力，預計2025年將佔據超過45%的市場。推動市場成長的因素包括癌症、糖尿病、心血管疾病（CVD）和自體免疫疾病等慢性疾病的日益普遍，蛋白質工程技術的快速發展，生物製藥行業的擴張以及產品在各種治療領域的廣泛應用。在北美，先進的醫療基礎設施、較高的疾病盛行率以及對研發的持續投入，使得該市場蓬勃發展。

癌症、糖尿病和自體免疫疾病等慢性病的日益普及是全球蛋白質療法市場的主要驅動力。根據世界衛生組織（WHO）統計，每年約有4,100萬人死於慢性病。其中，心血管疾病是首要死因，每年影響1,790萬人。其次是癌症（930萬人）、慢性呼吸道疾病（410萬人）和糖尿病（200萬人，包括所有因糖尿病腎病變導致的死亡）。這些疾病通常會發展為慢性病，需要採取特異性且複雜的治療策略，而蛋白質療法恰好能夠滿足這些需求。單株抗體是蛋白質療法的主要且最重要的產品類型，其設計目的是與疾病相關的特定分子相互作用，從而提供更精準、副作用更少的治療，進而推動蛋白質療法市場的成長。

在美國，蛋白質療法市場正因多種因素而不斷擴張，包括慢性病高發生率、強大的研發基礎設施以及支持性的醫療保健法規。美國癌症、糖尿病、自體免疫疾病和其他疾病的發生率居高不下，導致對先進治療方法的需求日益成長。根據可靠資訊來源估計，美國至少有1.29億人患有一種或多種主要慢性病。約4,200萬人患有兩種或兩種以上慢性病，1,200萬人患有五種或五種以上慢性病。單株抗體、胰島素類似物和酵素替代療法等新型生物製藥的患者核准正在增加。此外，美國食品藥物管理局（FDA）近期透過簡化生物製藥和生物相似藥的市場准入和競爭，提高了這些產品的可及性和成本效益，從而鞏固了其在蛋白質療法市場的佔有率。

蛋白質療法市場的發展趨勢：

擴大對生物製藥研發的投資

製藥業和研究機構對生物製藥和蛋白質藥物表現出越來越濃厚的興趣。這主要是因為這些產品具有高選擇性、高效性和靶向特定療法的能力。全球對生物製藥產業研發投入的關注正在推動蛋白質療法的發展。這些投資支持蛋白質工程、藥物發現和製劑最佳化等活動，從而開發出新型和改良的蛋白質療法。例如，2021年，全球生物製藥公司在研發方面投入了2,760億美元。這項投資分佈在全球4,191家公司，反映該領域對加強創新日益重視。此外，大量的研發資金使研究人員能夠探索新的治療標靶，最佳化分子功能，並進行大量的體外、體內和臨床試驗。這些努力透過開發針對各種疾病的新治療方法促進了市場成長。研發投入的增加也加速了蛋白質療法生產流程的商業化，降低了價格。這將促進蛋白質藥物的進一步商業性應用和市場擴張。

生物相似藥的擴張

生物相似藥市場的成長是推動市場發展的重要因素。生物相似藥是指與已核准的參考蛋白藥物高度相似的生物製藥。由於多種暢銷生物製藥的專利到期，生物相似藥市場正在顯著擴張。生物相似藥的出現為昂貴的蛋白療法提供了一種經濟有效的替代方案，使患者和醫療系統更容易獲得這些療法。這減輕了患者的治療成本負擔，間接推動了市場成長。生物相似藥的存在也促進了市場競爭。競爭會降低價格，從而擴大市場規模，並為生物相似藥生產商以及參考蛋白療法生產商的創新和改進創造空間。例如，2022年2月，百康生物製藥有限公司（Biocon Biologics Ltd.，百康生物製藥有限公司的子公司）簽署了一項最終商業協議，收購Viatris Inc.的生物相似藥業務。這些優勢使得該交易的估值達到33億美元。然而，近年來，生物相似藥的相關法規和指南不斷發展完善，為生物相似藥的研發和核准建立了清晰的路徑。這增強了醫療相關人員的信心，並擴大了生物相似藥的應用範圍。生物相似藥市場的擴張正在刺激蛋白質療法領域的進一步研發活動。製造商正致力於開發更先進、更具差異化的生物相似藥，這為蛋白質療法市場帶來了光明的前景。

人口老化的過程

由於老年人口的不斷成長，市場正顯著擴張。隨著全球人口老化，阿茲海默症、帕金森氏症、老齡化黃斑部病變和骨質疏鬆症等老齡化相關疾病的發生率也在上升。據估計，全球約有32.9%的成年人患有至少兩種慢性疾病。老年人面臨的這些特殊健康挑戰正在推動蛋白質療法的研發和應用。此外，蛋白質療法在療效和副作用方面優於傳統治療方法，直接影響老齡化相關疾病的治療。透過作用於特定的分子受體並針對這些疾病相關的分子過程，蛋白質療法有望提高治療標準和患者的生活品質。此外，隨著老化的加劇，對這些產品的需求也激增。各大製藥公司和研究機構正致力於開發新的蛋白質療法，以滿足老年族群的需求。人口老化也提升了蛋白質療法的市場潛力，促使生產者拓展產品線並提高產量。因此，蛋白質療法的可及性不斷提高，從而進一步擴大了市場。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球蛋白質治療藥物市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 單株抗體（mAbs）
  • 人類胰島素
  • 促紅血球生成素
  • 凝血因子
  • 融合蛋白
  • 其他

第7章 市場區隔：依治療領域分類

  • 代謝性疾病
  • 免疫系統疾病
  • 血液疾病
  • 癌症
  • 內分泌疾病
  • 遺傳性疾病
  • 其他

第8章 市場區隔：依功能分類

  • 酵素和調節活性
  • 特殊標靶化活動
  • 疫苗
  • 蛋白質診斷試劑

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Amgen Inc.
    • Abbott Laboratories
    • Abbvie Inc.
    • Baxter International Inc.
    • Biogen Inc.
    • Csl Behring LLC（CSL Limited）
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novo Nordisk A/S（Novo Holdings A/S）
    • Pfizer Inc.
Product Code: SR112026A2431

The global protein therapeutics market size was valued at USD 388.9 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 637.9 Billion by 2034, exhibiting a CAGR of 5.48% during 2026-2034. North America currently dominates the market, holding a significant market share of over 45% in 2025. The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases (CVDs), and autoimmune disorders, rapid technological advancements in protein engineering, the expanding biopharmaceutical industry, and the widespread product applications in diverse therapeutic areas are some factors propelling the market. In North America, the market is thriving due to the presence of advanced healthcare infrastructure, high disease prevalence, and ongoing investment in research and development (R&D).

The escalating prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is a key driver for the global protein therapeutics market. According to the World Health Organization (WHO), about 41 million people die from chronic diseases every year. Of this total, cardiovascular diseases are the biggest killers or 17.9 million people per year, cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million including all deaths caused by kidney diseases due to diabetes). These conditions are frequently chronic and need specific and complex treatment strategies, which are ideal for protein treatments. A large and important type of protein product, monoclonal antibodies, are designed to interact with specific molecules involved in diseases, offered more accurate treatments with less side effects, thus contributing to the protein therapeutics market growth.

In the United States, the protein therapeutics market is expanding due to several factors, including a high prevalence of chronic diseases, a strong R&D infrastructure, and supportive healthcare regulations. The country has a high prevalence of diseases and illnesses such as cancer, diabetes, auto immune and other illnesses therefore the need for advanced treatments. It is estimated from reliable sources that at least 129 million people in the country's population have at least one major chronic disease; 42 million people, two or more chronic diseases; and 12 million people, five or more chronic diseases. There is a growing approval of patients with new biologic drugs like the monoclonal antibodies, insulin analogs and enzyme replacement therapy. Furthermore, the U.S. Food and Drug Administration (FDA) has recently simplified the entry and competition for biologics and biosimilars, which improves access and costs of these products, thereby strengthening the protein therapeutics market share.

PROTEIN THERAPEUTICS MARKET TRENDS:

Growing biopharmaceutical research and development investments

Industry and research organizations are paying more attention to bio-pharmaceuticals and drugs based on proteins basically because they are highly selective, effective, and targeted. The global attention on R&D spending in the biopharmaceutical industry is facilitating the development of protein therapeutics. These investments finance activities that include protein engineering, drug discovery, and formulation optimization hence the development of new and enhanced protein therapeutic products. For example, worldwide biopharmaceutical corporations spent $276 billion on R&D processes in the year 2021. This investment spread over 4191 firms globally and reflected the increasing focus on enhancing innovation in the sector. In addition, a large amount of money going into R & D allows researchers to search for additional therapeutic targets, fine-tune the molecule for better function, and perform numerous in vitro in vivo, and clinical trials. The efforts also help in the growth of the market due to the development of new treatments for different diseases. Also, the rise in spending on R&D enhances the commercialization of production procedures of protein therapeutic products making them affordable. This facilitates further commercial utilization and market expansion of protein-based drugs.

Expansion of biosimilars

The growth of the biosimilar market is a significant contributor to the market. Biosimilars are biological products that are highly similar to an already approved reference protein medicinal product. Because of the expiration of patents on several high-selling biologics, the market for biosimilars is emerging significantly. The availability of biosimilars offers cost-effective alternatives to expensive protein therapeutics, thus making them more accessible to patients and healthcare systems. It increases the affordability of treatments to patients, thus indirectly driving the market into growth. Also, the existence of biosimilars helps create competition in the market. Competition makes prices reduce, hence expanding the market and giving room to innovate and improve among biosimilar manufacturers and also in the case of reference protein therapeutics companies. For instance, in February 2022, Biocon Biologics Ltd., a Biocon subsidiary, signed a definitive business agreement to acquire the biosimilars business of Viatris Inc. With such merit, the deal was set at US$ 3.3 Billion. However, regulation and guidance on biosimilars have evolved and have improved in recent years, creating a definite line of biosimilar development and approval. This has strengthened the healthcare community's confidence and hence increased biosimilar utilization. As the biosimilar market expands, it stimulates further R&D efforts in protein therapeutics. Manufacturers strive to develop more advanced and differentiated biosimilars, creating a positive protein therapeutics market outlook.

Rising aging population

The market is significantly growing due to the increase in population of the aging people. While the global population ages it is accompanied by increased occurrences of age-related illnesses and diseases like Alzheimer's, Parkinson's, macular degeneration, and osteoporosis. It was estimated that about 32.9% of adults globally suffer from at least two multiple chronic diseases. These specific health challenges that the aging population face, promote the development and application of protein therapeutics. In addition, protein therapeutics are directly effective in treating age-related diseases and have better advantages than traditional therapies in terms of efficiency and fewer side effects. They also act on selective molecular receptors and focus on the molecular processes of these diseases, which should elevate the standard of treatment and the quality of people's lives. Furthermore, the surging demand for these products increases with the aging population. Besides this, major pharmaceutical companies and research institutions are seeking new protein therapeutics that align with the needs of this group of people. Apart from this, the rising aging population provides a higher market potential for protein therapeutics, encouraging manufacturers to broaden product ranges and produce more. This results in increased availability of protein therapeutics and influences the expansion of the market further.

PROTEIN THERAPEUTICS INDUSTRY SEGMENTATION:

Analysis by Product:

  • Monoclonal Antibodies (mAbs)
  • Human Insulin
  • Erythropoietin
  • Clotting Factors
  • Fusion Protein
  • Others

Monoclonal Antibodies (mAbs) products stand as the largest product in 2025, holding over 49% of the market. mAbs are widely applied to cancer therapy, autoimmune disorders, and inflammatory diseases. These diseases are on the rise and with enhancement in the technologies for the development of antibodies, the rising demand for mAbs is contributing to the market expansion.

However, human insulin is an essential protein medicine required for the treatment of diabetes. The growth of incidence of diabetes across the world increases the demand for insulin and insulin analogs, which drives the growth of the market in this segment. Also, erythropoietin more commonly referred to as EPO is one of the most common therapeutic proteins utilized to raise red blood cells' levels in the body. It is used for anemia especially for patients with chronic kidney disease and patients under chemotherapy. Furthermore, with a higher patient population requiring the indication for EPO therapy, this segment is growing steadily.

Apart from this, clotting factors are proteins which are involved in blood clotting. They are utilized for the control of various types of bleeding disorders such as hemophilia. Consequently, the demand for clotting factors increases with the rise in the awareness, diagnosis and treatment of hemophilia. In addition, chimeric proteins wherein two or more functional protein domains have been joined together have received enormous interest in the development of new therapeutic agents. They offer specific methods of cure of different diseases such as cancer and autoimmune diseases, which is driving the growth of this segment.

Analysis by Therapy Area:

  • Metabolic Disorders
  • Immunological Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others

Metabolic disorders lead the market, holding the largest market share. Metabolic disorders encompass conditions such as diabetes, obesity, and hypercholesterolemia. Protein therapeutics and drugs like insulin for diabetes are vital in managing these diseases and conditions. The increase in the incidence of metabolic diseases and the need for effective therapies and targeted medications contribute to the growth of the segment.

Immunological disorders, auto-immune diseases, and inflammatory diseases are also some other large therapy areas for protein therapeutics. Small molecules like nitroglycerin operate on the immune system and engage in disease pathways. Some of the drugs classified as monoclonal antibodies, and other protein-based drugs also operate on the immune system and involve the disease pathway. Immunological diseases are on the rise, and the number of protein drugs for these diseases is also on the rise, so it is also driving the market.

Furthermore, cancer continues to be one of the major forces boosting the market growth. While protein and antibody-based medicines are amongst the first-line therapies, they are revolutionizing cancer treatment through monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. Global cancer cases are increasing along with the cure such as targeted therapy and immunotherapy, boosting the market in oncology.

Analysis by Function:

  • Enzymatic and Regulatory Activity
  • Special Targeting Activity
  • Vaccines
  • Protein Diagnostics

Protein therapeutics with enzymatic and regulatory activity are vital in modulating biological processes and metabolic pathways. These proteins act as enzymes, receptors, or signaling molecules, offering therapeutic benefits in various diseases. The development of novel protein therapeutics with specific enzymatic or regulatory functions drives market growth in this segment.

Special targeting activity refers to protein therapeutics targeting certain cells, tissues, or molecular targets. Monoclonal antibodies and antibody-drug conjugates are examples of protein therapeutics with special targeting activity. They can selectively acknowledge and adhere to particular molecules or cells, offering tailored treatments. The development of targeted therapies in diseases such as cancer as well as autoimmune diseases has boosted the growth of protein therapeutics in this segment.

Vaccines are another significant segment in the market. Protein-substance vaccines are based on proteins or peptides that produce an immune response and protect against infections. The rising concern for vaccination programs throughout the world, the development of new infectious diseases, and the need for new and better types of vaccines are bolstering the market demand.

Protein diagnostics involves using proteins or protein-based assays for diagnostic purposes. These diagnostics can identify certain proteins or biomarkers that are linked to diseases, and can help in the early diagnosis, disease management or even in tailoring the treatment. The need for better diagnostic tools in ever increasing and as such, protein diagnostics are on the rise which helps support the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 45%. The region is endowed with well-developed healthcare system, a large number of bioscience and biopharmaceutical firms, and high levels of research and development. The availability of prominent companies and high investments in protein therapeutics research has boosted the growth of the market in North America. Besides, the increased incidence of chronic diseases, a vast number of aging patients, and reasonable compensation policies also strengthen the market in the region.

Asia Pacific is in the process of becoming a rather fast-developing market. This region holds a large population base, higher healthcare spending and growing incidences of chronic diseases. There is an increasingly growing pace of biopharmaceutical industry development and innovation within the Asian nations including China, Japan and India. However, the increasing perception of the existence of personalized medicine and the increasing need for affordable treatment is contributing to the growth of the market in the region.

KEY REGIONAL TAKEAWAYS:

NORTH AMERICA PROTEIN THERAPEUTICS MARKET ANALYSIS

The protein therapeutics market in North America is witnessing robust growth due to a combination of advanced healthcare infrastructure, high disease prevalence, and significant investment in research and development (R&D). The region has one of the highest incidences of chronic diseases, including cancer, diabetes, and autoimmune disorders, which necessitate innovative and effective treatment options. With a well-established biotechnology sector, North America is a global leader in developing and commercializing protein-based therapeutics, including monoclonal antibodies and fusion proteins. Favorable regulatory frameworks, such as expedited drug approvals by the U.S. FDA, further accelerate the market growth. Additionally, the region benefits from a strong focus on personalized medicine, where protein therapeutics play a critical role in offering targeted therapies with improved patient outcomes.

UNITED STATES PROTEIN THERAPEUTICS MARKET ANALYSIS

The United States accounts for 75% share of the market in North America. The high prevalence of chronic diseases, such as diabetes, autoimmune disorders, and cancer, is driving the market for protein therapies in the country. With more than 37 million Americans living with diabetes as of 2023, there is a high need for insulin and other protein-based treatments. The need for cutting-edge biologics to treat age-related disorders is further fueled by the aging population, which is predicted to reach more than 78 million by 2040. The development of next-generation protein therapies, such as fusion proteins and antibody-drug conjugates, is being streamlined by technological developments like recombinant DNA technology and the manufacture of monoclonal antibodies.

Innovation has been aided by regulatory support, such as the FDA's accelerated approval processes for innovative biologics. Biopharmaceutical firms are making significant investments in research and development; in 2023, the United States will still be the world's largest market, generating about 60% of biopharmaceutical innovation. Furthermore, the manufacture of protein therapies is now more scalable due to the availability of a strong infrastructure for manufacturing and clinical trials. The industry is anticipated to be further supported by the rise of customized medicine and the launch of biosimilars, which provide affordable substitutes for pricy biologics without sacrificing efficacy or safety.

EUROPE PROTEIN THERAPEUTICS MARKET ANALYSIS

Growing chronic illness rates and a strong focus on healthcare innovation in the region are driving the market for protein therapies in Europe. The European Medicines Agency (EMA) recommended 77 medicines for marketing authorization in 2023, demonstrating the region's dedication to cutting-edge protein-based therapies. Since cancer accounts for 2.7 million new cases in Europe each year, there is a great need for targeted therapy using protein medicines like interferons and monoclonal antibodies. European governments and health institutions are making significant investments in biotechnology and personalized medicine, with programs such as Horizon Europe offering major financing for research and development. The market is led by nations with strong healthcare systems and high patient awareness, such as Germany, France, and the UK. Furthermore, the EU's cost-cutting measures are encouraging the growing acceptance of biosimilars, which is increasing market penetration by making protein-based medications more accessible.

ASIA PACIFIC PROTEIN THERAPEUTICS MARKET ANALYSIS

The market for protein therapies in Asia-Pacific is expanding quickly as a result of rising healthcare costs, an increase in the number of chronic illnesses, and the use of cutting-edge medical technology. Insulin and other protein-based therapies are essential in tackling this expanding healthcare issue in China and India, which have the highest diabetes populations in the world. Leaders in biopharmaceutical innovation, South Korea and Japan have made large expenditures in the development of biosimilars and monoclonal antibodies.

Demand is being increased by the burgeoning middle class and rising knowledge of sophisticated biologics in emerging economies. To lessen reliance on imports, the governments in the area are encouraging domestic manufacturing and research and development. China's "Healthy China 2030" policy, for instance, promotes the creation of innovative biopharmaceuticals, such as protein therapies. Furthermore, collaborations between regional and international pharmaceutical firms are augmenting the introduction of reasonably priced protein therapies throughout Asia-Pacific.

LATIN AMERICA PROTEIN THERAPEUTICS MARKET ANALYSIS

The rising incidence of chronic illnesses and the development of better healthcare facilities are driving the market for protein therapies in Latin America. To improve patient outcomes, nations with high incidences of diabetes and cancer, such as Brazil and Mexico, are implementing cutting-edge biologics. Government healthcare initiatives and increased investments in biopharmaceutical R&D are boosting the manufacturing and marketing of protein therapies. Additionally, the emergence of biosimilars, which provide affordable substitutes, is opening up more therapy possibilities in the area.

MIDDLE EAST AND AFRICA PROTEIN THERAPEUTICS MARKET ANALYSIS

The rising prevalence of chronic illnesses and a growing emphasis on expanding access to healthcare are driving the market for protein therapies. In line with their goal of modernizing healthcare systems, nations in the Middle East like as Saudi Arabia and the United Arab Emirates are making significant investments in biopharmaceuticals. Access to protein therapies, especially for conditions like diabetes and cancer, is being improved in Africa thanks to international partnerships and funding programs run by agencies like the WHO. Furthermore, local production facilities and awareness campaigns are progressively extending the reach of these cutting-edge remedies throughout the region.

COMPETITIVE LANDSCAPE:

Top companies are now investing heavily in scientific research with the aim of identifying new therapeutic targets and creating protein-based drugs with enhanced efficacy and safety profiles. They can use their skills in protein engineering, molecular biology, and biotechnology to create and optimize therapeutic proteins. Additionally, top companies form strategic collaborations with academic institutions, research organizations, and other pharmaceutical companies in order to acquire new technologies and expand their pipeline while accelerating the development process. Collaborations allow the parties to share knowledge, resources, and expertise with each other for innovation and for driving the market. Also, successful commercialization strategies play an important role in promoting market growth. These companies implement strong marketing and sales activities in order to offer their products to healthcare providers and patients worldwide. They perform detailed clinical trials, develop significant clinical data, and gain regulatory approval to access the market. The top companies also invest continually in manufacturing capabilities and quality control systems to be able to produce a consistent supply of their products to meet growing demand. These efforts at excellence in manufacturing thus help them in meeting the requirements of patients, healthcare providers, and payers, further driving the market.

The report provides a comprehensive analysis of the competitive landscape in the protein therapeutics market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • Abbott Laboratories
  • Abbvie Inc.
  • Baxter International Inc.
  • Biogen Inc.
  • Csl Behring L.L.C. (CSL Limited)
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novo Nordisk A/S (Novo Holdings A/S)
  • Pfizer Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What are protein therapeutics?

2. How big is the protein therapeutics market?

3. What is the expected growth rate of the global protein therapeutics market during 2026-2034?

4. What are the key factors driving the global protein therapeutics market?

5. What is the leading segment of the global protein therapeutics market based on the product?

6. What is the leading segment of the global protein therapeutics market based on therapy area?

7. What are the key regions in the global protein therapeutics market?

8. Who are the key players/companies in the global protein therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Protein Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Human Insulin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Erythropoietin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Clotting Factors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Fusion Protein
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Metabolic Disorders
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Immunological Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Hematological Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Hormonal Disorders
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Genetic Disorders
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Function

  • 8.1 Enzymatic and Regulatory Activity
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Special Targeting Activity
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Vaccines
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Protein Diagnostics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbott Laboratories
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Abbvie Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Baxter International Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Biogen Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Csl Behring L.L.C. (CSL Limited)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Eli Lilly and Company
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 SWOT Analysis
    • 14.3.9 Johnson & Johnson
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck & Co. Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novo Nordisk A/S (Novo Holdings A/S)
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Protein Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Protein Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Protein Therapeutics Market: Breakup by Product (in %), 2025
  • Figure 4: Global: Protein Therapeutics Market: Breakup by Therapy Area (in %), 2025
  • Figure 5: Global: Protein Therapeutics Market: Breakup by Function (in %), 2025
  • Figure 6: Global: Protein Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Protein Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Protein Therapeutics (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Protein Therapeutics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Protein Therapeutics (Human Insulin) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Protein Therapeutics (Human Insulin) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Protein Therapeutics (Erythropoietin) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Protein Therapeutics (Erythropoietin) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Protein Therapeutics (Clotting Factors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Protein Therapeutics (Clotting Factors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Protein Therapeutics (Fusion Protein) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Protein Therapeutics (Fusion Protein) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Protein Therapeutics (Other Products) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Protein Therapeutics (Other Products) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Protein Therapeutics (Metabolic Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Protein Therapeutics (Metabolic Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Protein Therapeutics (Immunological Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Protein Therapeutics (Immunological Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Protein Therapeutics (Hematological Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Protein Therapeutics (Hematological Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Protein Therapeutics (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Protein Therapeutics (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Protein Therapeutics (Hormonal Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Protein Therapeutics (Hormonal Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Protein Therapeutics (Genetic Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Protein Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Protein Therapeutics (Other Therapy Areas) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Protein Therapeutics (Other Therapy Areas) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Protein Therapeutics (Enzymatic and Regulatory Activity) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Protein Therapeutics (Enzymatic and Regulatory Activity) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Protein Therapeutics (Special Targeting Activity) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Protein Therapeutics (Special Targeting Activity) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Protein Therapeutics (Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Protein Therapeutics (Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Protein Therapeutics (Protein Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Protein Therapeutics (Protein Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: North America: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: North America: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: United States: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: United States: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Canada: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Canada: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Asia Pacific: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Asia Pacific: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: China: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: China: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Japan: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Japan: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: India: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: India: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: South Korea: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: South Korea: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Australia: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Australia: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Indonesia: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Indonesia: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Others: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Others: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Europe: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Europe: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Germany: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Germany: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: France: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: France: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: United Kingdom: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: United Kingdom: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Italy: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Italy: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Spain: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Spain: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Russia: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Russia: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Others: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Others: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Latin America: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Latin America: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Brazil: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Brazil: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Mexico: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Mexico: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Others: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Others: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Middle East and Africa: Protein Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Middle East and Africa: Protein Therapeutics Market: Breakup by Country (in %), 2025
  • Figure 90: Middle East and Africa: Protein Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Global: Protein Therapeutics Industry: SWOT Analysis
  • Figure 92: Global: Protein Therapeutics Industry: Value Chain Analysis
  • Figure 93: Global: Protein Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Protein Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Protein Therapeutics Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Protein Therapeutics Market Forecast: Breakup by Therapy Area (in Million USD), 2026-2034
  • Table 4: Global: Protein Therapeutics Market Forecast: Breakup by Function (in Million USD), 2026-2034
  • Table 5: Global: Protein Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Protein Therapeutics Market Structure
  • Table 7: Global: Protein Therapeutics Market: Key Players